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Preface
Engineered nucleases enable the targeted alteration of any DNA sequence in a wide range of cell
types and organisms. The newly-developed transcription activator-like effector nucleases
(TALENs) comprise a non-specific DNA-cleaving nuclease fused to a DNA-binding domain that
can be easily engineered so that TALENs can target essentially any sequence. The capability to
quickly and efficiently alter any gene sequence using TALENs promises to have profound impacts
on biological research and to yield potential therapeutic strategies for genetic diseases.
Introduction
Targeted genome editing is a broadly applicable approach for efficiently modifying
essentially any sequence of interest in living cells or organisms. This technology relies on
the use of engineered nucleases, that is, artificial proteins composed of a customizable
sequence-specific DNA-binding domain fused to a nuclease that cleaves DNA in a non-
sequence-specific manner. These targetable nucleases are used to induce double-strand
breaks (DSBs) into specific DNA sites, which are then repaired by mechanisms that can be
exploited to create sequence alterations at the cleavage site. Nuclease-mediated genome
editing enables genetic studies that were previously difficult or impossible to perform. This
technology might also provide therapeutic avenues for genetic disorders including
monogenic diseases such as sickle cell anemia or cystic fibrosis. Reflecting its broad
importance, genome editing with engineered nucleases was named “Method of the Year” for
2011 by Nature Methods.1
The vast majority of targeted genome editing described in the literature (including initial
foundational studies) has been performed using zinc finger nucleases (ZFNs) (Box 1). ZFNs
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have been used to modify endogenous genes in a wide range of organisms and cell types2.
Several types of genomic alterations can be introduced with ZFNs including point
mutations, deletions, insertions, inversions, duplications, and translocations, thus providing
researchers with unprecedented tools to perform genetic manipulations. Furthermore, ZFNs
can potentially be used for therapeutic purposes; for example, ZFNs designed to disrupt the
expression of the HIV co-receptor CCR5 (chemokine receptor 5) gene3 have entered Phase 2
clinical trials for treatment of HIV/AIDS.
Recently, transcription activator-like effector nucleases (TALENs) have rapidly emerged as
an alternative to ZFNs for genome editing and introducing targeted DSBs. TALENs are
similar to ZFNs and comprise a non-specific FokI nuclease domain fused to a customizable
DNA-binding domain. This DNA-binding domain is composed of highly conserved repeats
derived from transcription activator-like effectors (TALEs), which are proteins secreted by
Xanthomonas bacteria to alter transcription of genes in host plant cells4(Figure 1a and 1b).
TALENs have generated much interest and excitement because they can be very easily and
rapidly designed by researchers using a simple ‘protein-DNA code’ that relates modular
DNA-binding TALE repeat domains to individual bases in a target-binding site. Over the
last two years, leveraging technologies and methodologies previously developed for the use
of ZFNs, several groups have used TALENs to modify endogenous genes in yeast5, fruit
fly6, roundworm7, crickets8, zebrafish9–11, frog12, rat13, pig14, cow14, thale cress15, rice16,
silkworm17, and human somatic15, 18, 19 and pluripotent stem cells20 (Supplementary
information S1) and presumably the technique will continue to extend to additional
organisms. Furthermore, a recent large-scale test demonstrated that TALENs have a very
high success rate and can be used to target essentially any DNA sequence of interest in
human cells18 (Supplementary information S2). Although ZFNs and TALENs have not been
directly compared, many studies have shown that TALENs and ZFNs have comparable
efficiencies when targeted to the same gene9, 13, 18, 20. Thus, the ease of design, high rates of
cleavage activity, and the essentially limitless targeting range of TALENs make them
suitable for the use by non-specialist researchers.
In this Innovation article, we will first briefly describe the simple modular strategy used to
design customized TALE repeat DNA-binding domains and then review recent progress on
the use of TALENs to introduce different types of genome alterations in a range of
organisms and cell types. In addition, we provide a comparison of the various publicly
available methods for constructing TALENs. Finally, we outline important goals for future
research that will further enhance the utility of these tools for research and therapeutic
applications.
Custom TALE DNA-binding domains
The fundamental building block used to engineer the DNA-binding domain of TALENs is a
highly conserved repeat derived from naturally occurring TALEs encoded by Xanthomonas
proteobacteria. These TALEs are injected into host plant cells via a Type III secretion
system and bind to genomic DNA to alter transcription in these cells, thereby facilitating
pathogenic bacterial colonization.4 DNA binding by these TALEs is mediated by arrays of
highly conserved 33–35 amino acid repeats flanked by additional TALE-derived domains at
the amino- and carboxy-terminal ends of the array (Figure 1c).
Individual TALE repeats in an array each specify a single base of DNA determined by the
identities of two hypervariable residues typically found at positions 12 and 13 of the domain
(Figure 1c and d). Experimental evidence for this simple recognition code was first provided
by Bonas and colleagues in 2009.21 The researchers observed that the number of repeats in
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an array corresponded to the length of its target site and this insight enabled them to deduce
a simple correlation between the hypervariable residues and the base bound by each repeat.
Moreover, they found that a thymine is conserved at the position just 5’ to the base bound by
the first repeat in the array (Figure 1d). This group provided experimental evidence for the
TALE repeat code by constructing the first examples of engineered TALE repeat arrays with
novel specificities.21 The TALE repeat code was also confirmed by another group by
performing a computational analysis of the binding specificities of naturally occurring
TALEs22. Subsequent reports provided additional evidence that engineered TALE repeats
with desired specificities can be created using the code.19, 23–25
More recently, co-crystal structures of TALE DNA-binding domains bound to their cognate
sites have shown that individual repeats comprise two-helix v-shaped bundles that stack to
form a superhelix around the DNA and the hypervariable residues at positions 12 and 13 are
positioned in the DNA major-groove. The residues at position 8 and position 12 within the
same repeat make a contact with each other that may stabilize the structure of the domain
while the residues at position 13 can make base-specific contacts with the DNA.26, 27
Nearly all engineered TALE repeat arrays published to date use four domains with the
hypervariable residues NN, NI, HD and NG, for the recognition of G, A, C, and T,
respectively. Another repeat with hypervariable residues NK has been reported to be more
specific for G than the NN repeat (which can also recognize A)19, 22 but arrays using the NK
repeats show less activity than those using NN repeats.10, 28 More recently, a repeat with
hypervariable residues NH has been reported to be more specific than the NN repeat, but
with only slightly lower activity.28, 29 Additional studies with a greater number of repeat
arrays are needed to determine the optimal repeat domain for G recognition. It will also be
interesting to explore whether repeats bearing other hypervariable residue combinations will
have higher or different specificities for one or more DNA nucleotides.
Nuclease-mediated alterations
A substantial body of literature demonstrates that normal cellular repair of ZFN-induced
DSBs by non-homologous end-joining (NHEJ) or homology-directed repair (HDR) can be
exploited to introduce targeted genome alterations in a wide range of organisms and cell
types2, 30. NHEJ-mediated repair of a nuclease-induced DSB leads to the efficient
introduction of variable length insertion/deletion (indel) mutations that originate at the site
of the break (Figure 2a). Thus, NHEJ-mediated repair of DSBs introduced into gene coding
sequences will often yield frameshift mutations that can lead to knockout of gene function.
Alterantively, if a double-stranded DNA “donor template” is supplied, HDR of a nuclease-
induced DSB can be used to introduce precise nucleotide substitutions or insertions of up to
7.6 kb at or near the site of the break31 (Figure 2a). Recent work has also shown that
oligonucleotides can be used with ZFNs to introduce precise alterations, small insertions,
and large deletions32. ZFNs have been used to introduce NHEJ- or HDR-mediated gene
alterations in fruit fly33, 34, roundworm7, 35, zebrafish36, 37, rainbow trout38, catfish39, sea
urchin40, frog41, pig42, cattle43, cricket8, rabbit44, silkworm45, butterfly46, mouse47, 48,
rat49, 50, soybean51, 52, thale cress53, 54, corn55, tobacco56, petunia57, hamster cells58, and
human somatic59, 60 and pluripotent stem cells61–63. In most of these organisms and cell
types, the high absolute rates of mutagenesis that can be achieved with ZFNs have enabled
researchers to screen for mutations without the need for selection.
As summarized in Figure 2b, ZFNs and the I-SceI homing endonuclease have also been used
to induce other more complex types of genome alterations in mammalian cells. These
include large deletions induced by introduction of two DSBs with subsequent deletion of
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intervening sequence of up to 15 Mbps in length64, translocations induced by two DSBs
introduced on different chromosomes65, 66 and inversions of chromosomal sequence
between two DSBs induced on the same chromosome67. Given the requirement to introduce
two DSBs, it is not surprising that these more complex alterations are obtained with lower
efficiencies compared to alterations that are dependent on a single DSB.
Although TALENs were first described only two years ago, these nucleases have already
been utilized in a large number of applications. TALENs have been used to generate NHEJ-
mediated mutations in a wide variety of organisms with generally high efficiencies
(summarized in Supplementary information S1). TALENs have also been used to introduce
specific insertions in human somatic and pluripotent stem cells using double-stranded donor
templates.19, 20
Applications of Genome Editing
As noted above, the rapid development of customized ZFNs has already substantially
expanded the scope of genetic research that can be performed in a broad range of different
organisms and cell types. The high efficiencies of alterations observed have already inspired
efforts to use ZFNs as a potential therapeutic approach for genetic-based diseases. The
relative simplicity with which TALENs can be engineered will further spur efforts to
explore the research and therapeutic applications of customized nuclease technology. In this
section, we review recent progress on the use of TALENs in various organismic and cellular
contexts and briefly discuss prospects for their future applications.
Model organisms
As with ZFNs, TALENs have enabled efficient introduction of targeted alterations in a
number of model organisms that were previously difficult or impossible to manipulate
genetically such as fruit fly6, roundworm7, zebrafish9–11, frog12, rat13, and pig14. In
addition, TALENs have also been used to modify endogenous genes in cow14, cricket8, and
silkworm17. Most of these studies used a single TALEN pair to generate NHEJ-induced
knockout mutations but two of these reports also described the use of two TALEN pairs
targeted to the same chromosome to generate deletions and/or inversions of large
chromosomal segments14, 17. In addition, another recent study also used TALENs together
with short single-stranded DNA oligodeoxynucleotide donors to make precise insertions into
the zebrafish genome11. The ability to efficiently induce mutations in various organisms
should lead to the development of new animal models of human diseases. For example,
TALENs have been used to inactivate the LDL receptor gene in pigs, thereby generating a
model for familial hypercholesterolemia14.
Plants and Livestock
Unlike model organisms, which are typically selected for their rapid life cycles, many
agricultural plants and species have long reproductive cycles and therefore can take many
years to breed successfully. Nuclease-mediated editing of plants and agricultural animals
may greatly decrease the time required to generate new varieties of both species relative to
traditional breeding strategies. For example, using micropropagation strategies, some plant
species can be modified on the single cell level and then grown into mature plants. ZFNs
have been used to make targeted indels in soybean51, 52 and to introduce specific mutations
and transgene insertions that confer herbicide resistance in tobacco56 and corn55,
respectively. To date, TALENs have been used to make knockout mutations in
Arabidopsis15 and to introduce resistance to infection by Xanthomonas bacteria in rice by
disrupting the target sites of naturally occurring TALEs that contribute to pathogenicity16.
Gene-editing nucleases have also been used to make targeted NHEJ-induced indel mutations
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in pigs and cows14. In addition, large deletions and inversions of sequence greater than 6 kb
in length have been induced in pigs by targeting two TALEN pairs to the same
chromosome14.
Cell-based disease modeling
Gene-editing nucleases offer the potential to directly assess the impacts of gene disruption
and of specific sequence variants on gene function in somatic cell-based models of disease.
To date, TALENs have primarily been used to disrupt human genes via introduction of
NHEJ-induced indels into coding sequence15, 18, 19, 68–71. In principle, such loss-of-function
mutations could be used to create somatic cell-based models of disease. Alternatively,
precise insertions have also been introduced into endogenous human genes using HDR with
TALENs and a double-stranded homologous donor template plasmid19, 20. Targeted
insertions could be used to create endogenous gene fusions to fluorescent proteins or epitope
tags to visualize protein expression, distribution, or interactions. Beyond generation of such
fusions, HDR-based approaches might also be used to create isogenic human or other
mammalian cell lines bearing specific single nucleotide polymorphisms (SNPs) identified by
large-scale GWAS, ENCODE, or other sequencing projects, potentially enabling studies to
determine the functional significance of these sequence variants.
Therapeutics
In contrast to therapies that treat symptoms of genetic diseases, targeted nucleases offer the
potential to correct or disrupt gene products or sequences responsible for causing the
disorder. For example, recent studies have shown that ZFN-induced HDR can be used to
correct genetic mutations responsible for sickle cell anemia72 or alpha1-antitypsin disease73
or in the Parkinson’s disease-associated alpha-synuclein gene74 in patient-specific induced
pluripotent stem cells that have been reprogrammed from fibroblasts. These reports provide
important proofs-of-principle for autologous transplant strategies in which patient-derived
cells might be corrected ex vivo and then re-introduced back into patients with presumably
reduced probability of immune complications. Although these studies were performed with
ZFNs, TALEN-induced HDR in human pluripotent stem and somatic cells has also been
achieved20. Another potential strategy for therapy is to use nuclease-induced disruption via
NHEJ-mediated repair to abolish the activity of a gene. This type of approach is currently
being tested as a therapy for AIDS in which ZFNs are used to disrupt expression of the
CCR5 gene product required by certain strains of HIV as a co-receptor to infect cells3. The
ability to target essentially any DNA sequence with TALENs will undoubtedly motivate
exploration of both gene-correction and gene-disruption strategies for the treatment of a
wide range of genetic and other diseases.
Platforms for Engineering TALENs
The construction of DNA encoding engineered TALE repeat arrays can be challenging due
to the requirement to assemble multiple, nearly identical repeat sequences. Different
platforms have been designed to facilitate the assembly of plasmids encoding TALE repeat
arrays. These methods are depicted in Supplementary information S3 and can be grouped
into three broad categories: standard restriction enzyme and ligation-based cloning, “Golden
Gate” cloning, and solid-phase assembly. Detailed descriptions of these methods are
provided in Supplementary Information S2.
As summarized in Supplementary information S4, these platforms vary in their throughput,
molecular cloning techniques used, numbers of plasmids required (and time required to
prepare these DNAs), use of potentially mutagenic PCR, flexibility in the length of arrays
that can be constructed, ease with which the required reagents and detailed protocols can be
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acquired, and availability of author-supported web-based software for practicing the method.
Reagent kits for three of these methods are available to academics through the non-profit
plasmid distribution service Addgene (http://www.addgene.org/TALEN/). We have
established and maintain an active and open newsgroup (currently with over 660 members)
for discussion of TALE-related projects (http://groups.google.com/group/talengineering) as
well as a “one-stop” comprehensive website with links to protocols, reagents, software, and
other information about engineered TALE technology (http://www.TALengineering.org).
The specific architecture of a TALEN is an important factor for users to consider as they
choose an assembly method. Various TALEN architectures have been utilized to date and
one difference among these is the length and sequence composition of the amino- and
carboxy-terminal TALE-derived sequences that flank the TALE repeat array. In the earliest
TALENs described in the literature, large segments of naturally occurring TALE sequence
were used to join the FokI domain to the carboxy-terminal end of engineered TALE repeat
arrays.24 The TALEN framework was then refined by showing that nuclease activities could
be greatly enhanced by truncating the length of this carboxy-terminal TALE-derived
sequence19,68. In addition, although early studies used wild-type homodimeric FokI
nuclease domains, more recent reports10, 20, 75 have employed various obligate
heterodimeric domains originally developed and used with ZFNs76 (Box 1). Therefore,
because not all architectures are the same, we suggest that users should carefully consider
the reported activity levels and potential specificities of TALENs made on these different
frameworks when choosing a method of assembly. We note that as of the writing of this
review, the most extensively tested and validated TALEN framework remains that described
by Rebar and colleagues7, 9, 13, 18–20, 75, 77 (Supplementary information S1).
Future Directions
Although the development of engineered TALE technology has proceeded at an extremely
rapid pace over the past three years, many important questions remain to be addressed if
these proteins are to be used routinely for research and therapeutic applications. First,
although TALENs and ZFNs can induce specific HDR events, competing mutagenesis by
NHEJ can still lead to unwanted mutation of the original and, in some cases, the HDR-
altered allele. It will therefore be important to develop generalizable methods that tip the
balance away from NHEJ- and toward HDR-mediated repair. For example, recent
work7879, 80 has demonstrated that ZFN-derived nickases that cleave only one strand,
instead of both strands, of DNA can shift this balance, although the absolute rates of HDR-
mediated repair can be lower than those induced by the ZFNs from which they are derived.
Second, developing methods that enable definition of the genome-wide specificities of
TALENs will be critical to minimizing off-target NHEJ-mediated mutagenesis. Third,
optimization of methods for efficiently delivering TALENs or nucleic acids encoding them
into cells will also be an important area for future research. It will be interesting to
investigate whether purified native or modified TALEN proteins, like ZFNs81, might be
efficiently taken up directly by cells.
Another potential area for future exploration will be creation of fusion proteins harbouring
domains others than nucleases. TALE-based activators and repressors have already been
described (Box 2). However, one can also envision that engineered TALE repeat arrays
might be used to direct functional domains that induce epigenetic alterations (such as
covalent histone or DNA modifications) to specific genomic loci to induce stable, heritable
alterations in gene expression. TALE repeat arrays fused to a recombinase domain have
recently been described82, raising the exciting possibility of enabling targetable site-specific
recombination events.
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Engineered TALE technology promises to facilitate and enhance genetic manipulations in
different organisms and cell types. The simplicity with which TALENs can be designed
together with their robust success rates has already spurred much broader adoption of
genome editing technology. Although many interesting and challenging questions remain,
the accessibility and power of TALENs makes this technology an exciting and important
subject for future research and development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Box 1 | Engineered Zinc Finger Proteins
Cys2His2 zinc fingers are DNA-binding domains that each recognize approximately
three bps of DNA. Alteration of a small number of residues in or near an alpha-helix
within this domain can lead to changes in its DNA-binding specificity.83, 84 Engineered
zinc fingers can be joined together into more extended arrays capable of recognizing
longer DNA sequences. However, to obtain proteins with high affinities and specificities,
context-dependent effects between and among fingers in an array should be
considered.84–87 Sangamo BioSciences, Inc. has developed a proprietary and highly
effective platform for engineering zinc finger arrays36 and customized proteins made by
this method can be purchased from Sigma-Aldrich. In addition, various publicly available
methods for engineering zinc finger proteins have been described. Modular assembly of
individual pre-selected zinc finger domains provides a simple and rapid method for
creating customized arrays88 but the success rate of this strategy has been reported to be
low89. Additional methods that explicitly account for context-dependent effects among
zinc fingers in an array include: Oligomerized Pool Engineering (OPEN)90, Context-
Dependent Assembly (CoDA)52, and a bacterial one-hybrid (B1H) selection-based
system37. However, OPEN and B1H selections can be challenging to practice for some
non-specialist laboratories and OPEN, B1H, and CoDA have limitations in the range of
sequences they can be used to target. A large number of zinc finger arrays engineered
using these various methods have been fused to a non-specific nuclease domain from the
Type IIS FokI restriction enzyme to create zinc finger nucleases (ZFNs)91. The FokI
nuclease functions as a dimer and therefore two zinc finger arrays must be designed for
each target site. Early ZFNs used wild-type homodimeric FokI domains, which can form
unwanted dimers of the same monomeric ZFN. More recent studies have described
obligate heterodimeric FokI domains that reduce the formation of unwanted homodimeric
species and therefore have improved specificities.76 Engineered zinc finger arrays have
also been fused to transcriptional regulatory domains to create artificial transcription
factors capable of altering the expression of endogenous genes.92
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Box 2 | TALE-based Transcription Factors
As previously done with zinc fingers (Box 1), TALE repeat arrays have been fused to
transcriptional regulatory domains to create artificial transcription factors that can
activate or repress gene expression. To date, various studies have shown that TALE-
based activators and repressors can be used to modulate expression of endogenous genes
in plants and human cells, with changes in gene or protein expression in the range of two-
to 30-fold,15, 19, 29, 93–98 but the vast majority of these proteins show relatively modest
levels of activity. Although the high success rate and robust targeting range of dimeric
TALENs has been recently established,18 relatively less is known about these parameters
for monomeric engineered TALE-based transcriptional activators or repressors. The
epigenetic status (e.g.—chromatin or DNA methylation) of the target sites may influence
the activities of TALE-based transcription factors, as has been noted previously for zinc
finger-based activators99. In addition, it has been suggested that users should apply
computationally derived design guidelines (originally proposed for dimeric TALENs15)
to monomeric TALE-based transcription factors100 but no published experimental
support yet exists for this recommendation. Guidelines both for the selection of potential
target sites and for the use of particular TALE repeat domains (harboring NH residues at
the hypervariable positions) for recognition of G bases have been proposed.28 Large-
scale, systematic studies should prospectively determine whether adherence to these
recommendations (or the effects of varying other parameters such as the number of
repeats, the length and composition of TALE-derived protein sequences that flank the
TALE repeat array, or the nature of the transcriptional regulatory domain used) might
influence the activities and specificities of engineered TALE-based transcription factors.
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Figure 1. Overview of TALENs and TALE repeat arrays
a | Schematic diagram of a TALEN. TALE repeats are shown as colored cylinders with a
final carboxy-terminal truncated “half” repeat. Letters inside each repeat represent the two
hypervariable residues. TALE-derived amino- and carboxy-terminal domains required for
DNA-binding activity are shown as longer blue and grey cylinders, respectively. The non-
specific nuclease domain from the FokI endonuclease is shown as a larger orange cylinder. b
| TALENs bind and cleave as dimers on a target DNA site. Note that the TALE-derived
amino- and carboxy-terminal domains flanking the repeats may make some contacts to the
DNA. Cleavage by the FokI domains occurs in the “spacer” sequence that lies between the
two regions of the DNA bound by the two TALEN monomers. c | Schematic diagram of a
TALE-derived DNA-binding domain. The amino acid sequence of a single TALE repeat is
expanded below with the two hypervariable residues highlighted in orange and bold text. d |
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TALE-derived DNA-binding domain aligned with its target DNA sequence. Note the
matching of repeat domains to single bases in the target site according to the TALE code.
Also note the presence of a 5’ thymine preceding the first base bound by a TALE repeat.
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Figure 2. Nuclease-induced genome editing
a | Single nuclease-induced double-strand breaks (DSBs) in a gene locus can be repaired by
either NHEJ (thin black arrow) or HDR (thick black arrows). NHEJ-mediated repair leads to
introduction of variable length indel mutations. HDR with double-stranded DNA “donor
templates” can lead to the introduction of precise nucleotide substitutions or insertions. b |
Introduction of two nuclease-induced DSBs in cis on the same chromosome can lead to
deletion of the intervening sequence or inversion (left panel) and introduction of two
nuclease-induced DSBs on two different chromosomes can lead to the formation of
translocations (right panel).
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